1. Home
  2. SNES vs XAIR Comparison

SNES vs XAIR Comparison

Compare SNES & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SenesTech Inc.

SNES

SenesTech Inc.

HOLD

Current Price

$1.76

Market Cap

12.1M

Sector

Industrials

ML Signal

HOLD

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

HOLD

Current Price

$0.74

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNES
XAIR
Founded
2004
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
10.1M
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
SNES
XAIR
Price
$1.76
$0.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
45.9K
149.3K
Earning Date
03-12-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
77.99
62.09
EPS
N/A
N/A
Revenue
$600,000.00
$3,705,000.00
Revenue This Year
$29.00
$122.00
Revenue Next Year
$95.04
$58.15
P/E Ratio
N/A
N/A
Revenue Growth
132.56
219.67
52 Week Low
$1.30
$0.15
52 Week High
$5.99
$3.78

Technical Indicators

Market Signals
Indicator
SNES
XAIR
Relative Strength Index (RSI) 40.82 32.67
Support Level $1.67 $0.67
Resistance Level $2.26 $1.25
Average True Range (ATR) 0.18 0.06
MACD -0.03 0.00
Stochastic Oscillator 5.00 0.88

Price Performance

Historical Comparison
SNES
XAIR

About SNES SenesTech Inc.

SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.

About XAIR Beyond Air Inc.

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Share on Social Networks: